Sarepta says it won’t comply with FDA request to stop shipping gene therapy Elevidys Reuters Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys The New York Times Sarepta shares plunge 40% as future of its gene therapy appears at risk CNBC Third death from a Sarepta gene therapy biocentury.com We are mothers of Duchenne patients. Recent setbacks with Sarepta must not …
Read More »